4A85.00

ICD-11 MMS 2026-01

Drug-induced liver hypersensitivity disease

Description

Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine.

Index terms

  • Drug-induced liver hypersensitivity disease
  • Immune-mediated DILI - [drug-induced liver injury]
  • medicament-induced liver hypersensitivity disease

Exclusions from above levels

  • 02 – Neoplasms
  • 18 – Complications of pregnancy, childbirth and the puerperium
  • 20 – Developmental anomalies

Sibling codes

  • 4A85.01 – Drug-induced kidney hypersensitivity
  • 4A85.02 – Drug-induced cytopenia
  • 4A85.03 – Drug-induced vasculitis
  • 4A85.04 – Multiple drug hypersensitivity syndrome
  • 4A85.0Y – Drug hypersensitivity of other specified type
  • 4A85.0Z – Drug hypersensitivity of unspecified type

Foundation entity

Drug-induced liver hypersensitivity disease – http://id.who.int/icd/entity/674464254

Allowed postcoordination axes

Part of: 4A85.0: Drug or pharmacological agents hypersensitivity › 4A85: Complex allergic or hypersensitivity conditions › 04: Diseases of the immune system